Medpace Board Approves $1 Billion Stock Repurchase Authorization

Your call?🐂 Bullish🐻 Bearish

$1B

stock repurchase authorization

Revenue rose 8.5% year over year to $716 million, and GAAP diluted EPS was $4.84. Medpace forecast 2026 revenue of $2.835 billion to $2.855 billion.